nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—RAF1—lung cancer	0.189	0.47	CbGaD
Dabrafenib—LIMK1—Crizotinib—lung cancer	0.158	0.41	CbGbCtD
Dabrafenib—BRAF—lung cancer	0.131	0.326	CbGaD
Dabrafenib—ABCG2—lung cancer	0.0582	0.145	CbGaD
Dabrafenib—ABCB1—lung cancer	0.0242	0.0602	CbGaD
Dabrafenib—SLCO1B3—Paclitaxel—lung cancer	0.0164	0.0427	CbGbCtD
Dabrafenib—ABCG2—Topotecan—lung cancer	0.0153	0.0399	CbGbCtD
Dabrafenib—ABCG2—Gefitinib—lung cancer	0.014	0.0365	CbGbCtD
Dabrafenib—ABCG2—Teniposide—lung cancer	0.0136	0.0354	CbGbCtD
Dabrafenib—SLCO1B3—Docetaxel—lung cancer	0.0118	0.0308	CbGbCtD
Dabrafenib—SLCO1B1—Irinotecan—lung cancer	0.00942	0.0245	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—lung cancer	0.00856	0.0223	CbGbCtD
Dabrafenib—ABCG2—Erlotinib—lung cancer	0.00828	0.0216	CbGbCtD
Dabrafenib—ABCG2—Paclitaxel—lung cancer	0.00758	0.0197	CbGbCtD
Dabrafenib—ABCG2—Irinotecan—lung cancer	0.00748	0.0195	CbGbCtD
Dabrafenib—ABCG2—Cisplatin—lung cancer	0.0061	0.0159	CbGbCtD
Dabrafenib—ABCG2—Etoposide—lung cancer	0.00599	0.0156	CbGbCtD
Dabrafenib—ABCB1—Topotecan—lung cancer	0.00552	0.0144	CbGbCtD
Dabrafenib—ABCG2—Docetaxel—lung cancer	0.00548	0.0143	CbGbCtD
Dabrafenib—ABCB1—Gefitinib—lung cancer	0.00505	0.0132	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—lung cancer	0.00498	0.013	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—lung cancer	0.0046	0.012	CbGbCtD
Dabrafenib—CYP2C8—Erlotinib—lung cancer	0.00441	0.0115	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—lung cancer	0.00409	0.0106	CbGbCtD
Dabrafenib—CYP2C8—Paclitaxel—lung cancer	0.00404	0.0105	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—lung cancer	0.00396	0.0103	CbGbCtD
Dabrafenib—ABCB1—Vinorelbine—lung cancer	0.00389	0.0101	CbGbCtD
Dabrafenib—CYP3A4—Topotecan—lung cancer	0.00331	0.00862	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—lung cancer	0.0032	0.00834	CbGbCtD
Dabrafenib—CYP2C8—Etoposide—lung cancer	0.00319	0.00831	CbGbCtD
Dabrafenib—ABCB1—Crizotinib—lung cancer	0.0031	0.00806	CbGbCtD
Dabrafenib—CYP3A4—Gefitinib—lung cancer	0.00303	0.00788	CbGbCtD
Dabrafenib—ABCB1—Gemcitabine—lung cancer	0.00303	0.00788	CbGbCtD
Dabrafenib—ABCB1—Erlotinib—lung cancer	0.00299	0.00778	CbGbCtD
Dabrafenib—CYP3A4—Teniposide—lung cancer	0.00293	0.00764	CbGbCtD
Dabrafenib—ABCB1—Paclitaxel—lung cancer	0.00273	0.00712	CbGbCtD
Dabrafenib—ABCB1—Irinotecan—lung cancer	0.0027	0.00702	CbGbCtD
Dabrafenib—ABCB1—Vinblastine—lung cancer	0.0024	0.00624	CbGbCtD
Dabrafenib—CYP3A4—Vinorelbine—lung cancer	0.00233	0.00607	CbGbCtD
Dabrafenib—ABCB1—Cisplatin—lung cancer	0.0022	0.00572	CbGbCtD
Dabrafenib—ABCB1—Etoposide—lung cancer	0.00216	0.00562	CbGbCtD
Dabrafenib—ABCB1—Docetaxel—lung cancer	0.00198	0.00515	CbGbCtD
Dabrafenib—RAF1—Topotecan—Irinotecan—lung cancer	0.00189	1	CbGdCrCtD
Dabrafenib—CYP3A4—Crizotinib—lung cancer	0.00186	0.00483	CbGbCtD
Dabrafenib—CYP3A4—Erlotinib—lung cancer	0.00179	0.00466	CbGbCtD
Dabrafenib—CYP3A4—Paclitaxel—lung cancer	0.00164	0.00426	CbGbCtD
Dabrafenib—CYP3A4—Irinotecan—lung cancer	0.00162	0.00421	CbGbCtD
Dabrafenib—ABCB1—Doxorubicin—lung cancer	0.00147	0.00384	CbGbCtD
Dabrafenib—SIK1—mammary gland—lung cancer	0.00147	0.0838	CbGeAlD
Dabrafenib—CYP3A4—Vinblastine—lung cancer	0.00144	0.00374	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—lung cancer	0.00143	0.00372	CbGbCtD
Dabrafenib—NEK11—lung—lung cancer	0.00141	0.0801	CbGeAlD
Dabrafenib—CYP3A4—Etoposide—lung cancer	0.00129	0.00337	CbGbCtD
Dabrafenib—CYP3A4—Docetaxel—lung cancer	0.00118	0.00308	CbGbCtD
Dabrafenib—SIK1—respiratory system—lung cancer	0.000982	0.0558	CbGeAlD
Dabrafenib—NEK11—lymph node—lung cancer	0.000963	0.0548	CbGeAlD
Dabrafenib—CYP3A4—Doxorubicin—lung cancer	0.000883	0.0023	CbGbCtD
Dabrafenib—SLCO1B1—mammary gland—lung cancer	0.000877	0.0499	CbGeAlD
Dabrafenib—SIK1—bronchus—lung cancer	0.000808	0.0459	CbGeAlD
Dabrafenib—RAF1—respiratory system—lung cancer	0.000781	0.0444	CbGeAlD
Dabrafenib—LIMK1—lymph node—lung cancer	0.000689	0.0392	CbGeAlD
Dabrafenib—BRAF—bone marrow—lung cancer	0.000687	0.0391	CbGeAlD
Dabrafenib—SIK1—cardiac atrium—lung cancer	0.000681	0.0388	CbGeAlD
Dabrafenib—RAF1—epithelium—lung cancer	0.000653	0.0371	CbGeAlD
Dabrafenib—RAF1—bronchus—lung cancer	0.000643	0.0366	CbGeAlD
Dabrafenib—BRAF—lung—lung cancer	0.000623	0.0354	CbGeAlD
Dabrafenib—RAF1—trachea—lung cancer	0.000577	0.0328	CbGeAlD
Dabrafenib—SIK1—bone marrow—lung cancer	0.000575	0.0327	CbGeAlD
Dabrafenib—RAF1—cardiac atrium—lung cancer	0.000542	0.0308	CbGeAlD
Dabrafenib—SLCO1B3—lung—lung cancer	0.000537	0.0305	CbGeAlD
Dabrafenib—SIK1—lung—lung cancer	0.000521	0.0296	CbGeAlD
Dabrafenib—CYP2C8—mammary gland—lung cancer	0.000499	0.0284	CbGeAlD
Dabrafenib—RAF1—bone marrow—lung cancer	0.000458	0.026	CbGeAlD
Dabrafenib—BRAF—lymph node—lung cancer	0.000426	0.0242	CbGeAlD
Dabrafenib—RAF1—lung—lung cancer	0.000415	0.0236	CbGeAlD
Dabrafenib—SIK1—lymph node—lung cancer	0.000357	0.0203	CbGeAlD
Dabrafenib—RAF1—lymph node—lung cancer	0.000284	0.0161	CbGeAlD
Dabrafenib—ABCG2—bone marrow—lung cancer	0.000189	0.0108	CbGeAlD
Dabrafenib—ABCG2—lung—lung cancer	0.000172	0.00976	CbGeAlD
Dabrafenib—ABCB1—respiratory system—lung cancer	0.000159	0.00906	CbGeAlD
Dabrafenib—ABCB1—epithelium—lung cancer	0.000133	0.00757	CbGeAlD
Dabrafenib—ABCB1—trachea—lung cancer	0.000118	0.0067	CbGeAlD
Dabrafenib—ABCG2—lymph node—lung cancer	0.000117	0.00667	CbGeAlD
Dabrafenib—ABCB1—bone marrow—lung cancer	9.34e-05	0.00531	CbGeAlD
Dabrafenib—ABCB1—lung—lung cancer	8.46e-05	0.00481	CbGeAlD
Dabrafenib—ABCB1—lymph node—lung cancer	5.79e-05	0.00329	CbGeAlD
Dabrafenib—Abdominal discomfort—Methotrexate—lung cancer	4.66e-05	0.000449	CcSEcCtD
Dabrafenib—Fatigue—Gemcitabine—lung cancer	4.66e-05	0.000449	CcSEcCtD
Dabrafenib—Constipation—Gemcitabine—lung cancer	4.62e-05	0.000445	CcSEcCtD
Dabrafenib—Nausea—Erlotinib—lung cancer	4.62e-05	0.000445	CcSEcCtD
Dabrafenib—Dry mouth—Paclitaxel—lung cancer	4.62e-05	0.000444	CcSEcCtD
Dabrafenib—Diarrhoea—Vinorelbine—lung cancer	4.6e-05	0.000443	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Cisplatin—lung cancer	4.59e-05	0.000442	CcSEcCtD
Dabrafenib—Infection—Etoposide—lung cancer	4.59e-05	0.000441	CcSEcCtD
Dabrafenib—Blood creatinine increased—Doxorubicin—lung cancer	4.56e-05	0.000439	CcSEcCtD
Dabrafenib—Back pain—Docetaxel—lung cancer	4.55e-05	0.000438	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—lung cancer	4.55e-05	0.000438	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Irinotecan—lung cancer	4.54e-05	0.000437	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—lung cancer	4.53e-05	0.000436	CcSEcCtD
Dabrafenib—Oedema—Paclitaxel—lung cancer	4.53e-05	0.000436	CcSEcCtD
Dabrafenib—Thrombocytopenia—Etoposide—lung cancer	4.52e-05	0.000435	CcSEcCtD
Dabrafenib—Muscle spasms—Docetaxel—lung cancer	4.52e-05	0.000435	CcSEcCtD
Dabrafenib—Infection—Paclitaxel—lung cancer	4.5e-05	0.000433	CcSEcCtD
Dabrafenib—Skin disorder—Etoposide—lung cancer	4.48e-05	0.000432	CcSEcCtD
Dabrafenib—Dry skin—Doxorubicin—lung cancer	4.46e-05	0.00043	CcSEcCtD
Dabrafenib—Hyperhidrosis—Etoposide—lung cancer	4.46e-05	0.00043	CcSEcCtD
Dabrafenib—Dizziness—Vinorelbine—lung cancer	4.45e-05	0.000428	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—lung cancer	4.45e-05	0.000428	CcSEcCtD
Dabrafenib—Nervous system disorder—Paclitaxel—lung cancer	4.44e-05	0.000427	CcSEcCtD
Dabrafenib—Hypokalaemia—Doxorubicin—lung cancer	4.43e-05	0.000427	CcSEcCtD
Dabrafenib—Thrombocytopenia—Paclitaxel—lung cancer	4.43e-05	0.000427	CcSEcCtD
Dabrafenib—Skin disorder—Paclitaxel—lung cancer	4.4e-05	0.000423	CcSEcCtD
Dabrafenib—Abdominal pain—Irinotecan—lung cancer	4.39e-05	0.000422	CcSEcCtD
Dabrafenib—Body temperature increased—Irinotecan—lung cancer	4.39e-05	0.000422	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—lung cancer	4.39e-05	0.000422	CcSEcCtD
Dabrafenib—Decreased appetite—Cisplatin—lung cancer	4.38e-05	0.000422	CcSEcCtD
Dabrafenib—Hyperhidrosis—Paclitaxel—lung cancer	4.38e-05	0.000421	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—lung cancer	4.36e-05	0.000419	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Cisplatin—lung cancer	4.35e-05	0.000419	CcSEcCtD
Dabrafenib—Anaemia—Docetaxel—lung cancer	4.34e-05	0.000418	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—lung cancer	4.33e-05	0.000417	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—lung cancer	4.33e-05	0.000417	CcSEcCtD
Dabrafenib—Hypotension—Etoposide—lung cancer	4.31e-05	0.000415	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—lung cancer	4.3e-05	0.000414	CcSEcCtD
Dabrafenib—Vomiting—Vinorelbine—lung cancer	4.28e-05	0.000412	CcSEcCtD
Dabrafenib—Body temperature increased—Gemcitabine—lung cancer	4.27e-05	0.000411	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—lung cancer	4.26e-05	0.00041	CcSEcCtD
Dabrafenib—Rash—Vinorelbine—lung cancer	4.24e-05	0.000408	CcSEcCtD
Dabrafenib—Dermatitis—Vinorelbine—lung cancer	4.24e-05	0.000408	CcSEcCtD
Dabrafenib—Hypotension—Paclitaxel—lung cancer	4.23e-05	0.000407	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—lung cancer	4.23e-05	0.000407	CcSEcCtD
Dabrafenib—Headache—Vinorelbine—lung cancer	4.22e-05	0.000406	CcSEcCtD
Dabrafenib—Leukopenia—Docetaxel—lung cancer	4.21e-05	0.000405	CcSEcCtD
Dabrafenib—Haematuria—Methotrexate—lung cancer	4.13e-05	0.000398	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—lung cancer	4.13e-05	0.000397	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Paclitaxel—lung cancer	4.12e-05	0.000397	CcSEcCtD
Dabrafenib—Cough—Docetaxel—lung cancer	4.1e-05	0.000395	CcSEcCtD
Dabrafenib—Insomnia—Paclitaxel—lung cancer	4.09e-05	0.000394	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—lung cancer	4.09e-05	0.000394	CcSEcCtD
Dabrafenib—Hypersensitivity—Irinotecan—lung cancer	4.09e-05	0.000394	CcSEcCtD
Dabrafenib—Hypertension—Docetaxel—lung cancer	4.06e-05	0.000391	CcSEcCtD
Dabrafenib—Decreased appetite—Etoposide—lung cancer	4.01e-05	0.000386	CcSEcCtD
Dabrafenib—Arthralgia—Docetaxel—lung cancer	4e-05	0.000385	CcSEcCtD
Dabrafenib—Myalgia—Docetaxel—lung cancer	4e-05	0.000385	CcSEcCtD
Dabrafenib—Nausea—Vinorelbine—lung cancer	4e-05	0.000385	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Etoposide—lung cancer	3.98e-05	0.000384	CcSEcCtD
Dabrafenib—Body temperature increased—Cisplatin—lung cancer	3.98e-05	0.000383	CcSEcCtD
Dabrafenib—Asthenia—Irinotecan—lung cancer	3.98e-05	0.000383	CcSEcCtD
Dabrafenib—Fatigue—Etoposide—lung cancer	3.98e-05	0.000383	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	3.97e-05	0.000383	CcSEcCtD
Dabrafenib—Constipation—Etoposide—lung cancer	3.95e-05	0.00038	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—lung cancer	3.94e-05	0.000379	CcSEcCtD
Dabrafenib—Decreased appetite—Paclitaxel—lung cancer	3.93e-05	0.000379	CcSEcCtD
Dabrafenib—Dry mouth—Docetaxel—lung cancer	3.91e-05	0.000377	CcSEcCtD
Dabrafenib—Haemoglobin—Methotrexate—lung cancer	3.91e-05	0.000376	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Paclitaxel—lung cancer	3.91e-05	0.000376	CcSEcCtD
Dabrafenib—Fatigue—Paclitaxel—lung cancer	3.9e-05	0.000376	CcSEcCtD
Dabrafenib—Haemorrhage—Methotrexate—lung cancer	3.89e-05	0.000375	CcSEcCtD
Dabrafenib—Asthenia—Gemcitabine—lung cancer	3.88e-05	0.000373	CcSEcCtD
Dabrafenib—Constipation—Paclitaxel—lung cancer	3.87e-05	0.000373	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—lung cancer	3.84e-05	0.00037	CcSEcCtD
Dabrafenib—Oedema—Docetaxel—lung cancer	3.84e-05	0.000369	CcSEcCtD
Dabrafenib—Pruritus—Gemcitabine—lung cancer	3.82e-05	0.000368	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—lung cancer	3.81e-05	0.000367	CcSEcCtD
Dabrafenib—Infection—Docetaxel—lung cancer	3.81e-05	0.000367	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—lung cancer	3.8e-05	0.000366	CcSEcCtD
Dabrafenib—Diarrhoea—Irinotecan—lung cancer	3.8e-05	0.000365	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Etoposide—lung cancer	3.77e-05	0.000363	CcSEcCtD
Dabrafenib—Nervous system disorder—Docetaxel—lung cancer	3.76e-05	0.000362	CcSEcCtD
Dabrafenib—Thrombocytopenia—Docetaxel—lung cancer	3.76e-05	0.000362	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—lung cancer	3.75e-05	0.000361	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—lung cancer	3.75e-05	0.000361	CcSEcCtD
Dabrafenib—Skin disorder—Docetaxel—lung cancer	3.73e-05	0.000359	CcSEcCtD
Dabrafenib—Hypersensitivity—Cisplatin—lung cancer	3.71e-05	0.000357	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Paclitaxel—lung cancer	3.7e-05	0.000356	CcSEcCtD
Dabrafenib—Diarrhoea—Gemcitabine—lung cancer	3.7e-05	0.000356	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—lung cancer	3.69e-05	0.000355	CcSEcCtD
Dabrafenib—Dizziness—Irinotecan—lung cancer	3.67e-05	0.000353	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—lung cancer	3.66e-05	0.000352	CcSEcCtD
Dabrafenib—Abdominal pain—Etoposide—lung cancer	3.65e-05	0.000351	CcSEcCtD
Dabrafenib—Body temperature increased—Etoposide—lung cancer	3.65e-05	0.000351	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—lung cancer	3.65e-05	0.000351	CcSEcCtD
Dabrafenib—Eye disorder—Methotrexate—lung cancer	3.64e-05	0.00035	CcSEcCtD
Dabrafenib—Asthenia—Cisplatin—lung cancer	3.61e-05	0.000348	CcSEcCtD
Dabrafenib—Hypotension—Docetaxel—lung cancer	3.58e-05	0.000345	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—lung cancer	3.58e-05	0.000344	CcSEcCtD
Dabrafenib—Abdominal pain—Paclitaxel—lung cancer	3.58e-05	0.000344	CcSEcCtD
Dabrafenib—Body temperature increased—Paclitaxel—lung cancer	3.58e-05	0.000344	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—lung cancer	3.54e-05	0.000341	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—lung cancer	3.53e-05	0.00034	CcSEcCtD
Dabrafenib—Vomiting—Irinotecan—lung cancer	3.53e-05	0.00034	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—lung cancer	3.52e-05	0.000338	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—lung cancer	3.51e-05	0.000338	CcSEcCtD
Dabrafenib—Rash—Irinotecan—lung cancer	3.5e-05	0.000337	CcSEcCtD
Dabrafenib—Dermatitis—Irinotecan—lung cancer	3.5e-05	0.000336	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Docetaxel—lung cancer	3.49e-05	0.000336	CcSEcCtD
Dabrafenib—Chills—Methotrexate—lung cancer	3.49e-05	0.000336	CcSEcCtD
Dabrafenib—Headache—Irinotecan—lung cancer	3.48e-05	0.000335	CcSEcCtD
Dabrafenib—Insomnia—Docetaxel—lung cancer	3.47e-05	0.000334	CcSEcCtD
Dabrafenib—Diarrhoea—Cisplatin—lung cancer	3.45e-05	0.000332	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—lung cancer	3.44e-05	0.000331	CcSEcCtD
Dabrafenib—Vomiting—Gemcitabine—lung cancer	3.44e-05	0.000331	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—lung cancer	3.41e-05	0.000328	CcSEcCtD
Dabrafenib—Rash—Gemcitabine—lung cancer	3.41e-05	0.000328	CcSEcCtD
Dabrafenib—Dermatitis—Gemcitabine—lung cancer	3.41e-05	0.000328	CcSEcCtD
Dabrafenib—Hypersensitivity—Etoposide—lung cancer	3.4e-05	0.000327	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—lung cancer	3.39e-05	0.000326	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—lung cancer	3.39e-05	0.000326	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—lung cancer	3.39e-05	0.000326	CcSEcCtD
Dabrafenib—Headache—Gemcitabine—lung cancer	3.39e-05	0.000326	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—lung cancer	3.37e-05	0.000324	CcSEcCtD
Dabrafenib—Decreased appetite—Docetaxel—lung cancer	3.33e-05	0.000321	CcSEcCtD
Dabrafenib—Hypersensitivity—Paclitaxel—lung cancer	3.33e-05	0.000321	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—lung cancer	3.33e-05	0.00032	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—lung cancer	3.32e-05	0.00032	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Docetaxel—lung cancer	3.31e-05	0.000319	CcSEcCtD
Dabrafenib—Asthenia—Etoposide—lung cancer	3.31e-05	0.000319	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—lung cancer	3.31e-05	0.000319	CcSEcCtD
Dabrafenib—Fatigue—Docetaxel—lung cancer	3.31e-05	0.000318	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—lung cancer	3.3e-05	0.000318	CcSEcCtD
Dabrafenib—Nausea—Irinotecan—lung cancer	3.3e-05	0.000317	CcSEcCtD
Dabrafenib—Constipation—Docetaxel—lung cancer	3.28e-05	0.000316	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—lung cancer	3.28e-05	0.000315	CcSEcCtD
Dabrafenib—Pruritus—Etoposide—lung cancer	3.27e-05	0.000314	CcSEcCtD
Dabrafenib—Asthenia—Paclitaxel—lung cancer	3.25e-05	0.000313	CcSEcCtD
Dabrafenib—Nausea—Gemcitabine—lung cancer	3.21e-05	0.000309	CcSEcCtD
Dabrafenib—Vomiting—Cisplatin—lung cancer	3.2e-05	0.000308	CcSEcCtD
Dabrafenib—Pruritus—Paclitaxel—lung cancer	3.2e-05	0.000308	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—lung cancer	3.19e-05	0.000307	CcSEcCtD
Dabrafenib—Rash—Cisplatin—lung cancer	3.18e-05	0.000306	CcSEcCtD
Dabrafenib—Dermatitis—Cisplatin—lung cancer	3.17e-05	0.000305	CcSEcCtD
Dabrafenib—Diarrhoea—Etoposide—lung cancer	3.16e-05	0.000304	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—lung cancer	3.15e-05	0.000303	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Docetaxel—lung cancer	3.14e-05	0.000302	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—lung cancer	3.13e-05	0.000301	CcSEcCtD
Dabrafenib—Diarrhoea—Paclitaxel—lung cancer	3.1e-05	0.000298	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—lung cancer	3.06e-05	0.000294	CcSEcCtD
Dabrafenib—Dizziness—Etoposide—lung cancer	3.05e-05	0.000294	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—lung cancer	3.04e-05	0.000293	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—lung cancer	3.04e-05	0.000292	CcSEcCtD
Dabrafenib—Body temperature increased—Docetaxel—lung cancer	3.03e-05	0.000292	CcSEcCtD
Dabrafenib—Abdominal pain—Docetaxel—lung cancer	3.03e-05	0.000292	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—lung cancer	3.03e-05	0.000292	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—lung cancer	3.02e-05	0.000291	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—lung cancer	3.01e-05	0.00029	CcSEcCtD
Dabrafenib—Dizziness—Paclitaxel—lung cancer	2.99e-05	0.000288	CcSEcCtD
Dabrafenib—Nausea—Cisplatin—lung cancer	2.99e-05	0.000288	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—lung cancer	2.98e-05	0.000287	CcSEcCtD
Dabrafenib—Cough—Methotrexate—lung cancer	2.96e-05	0.000285	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—lung cancer	2.95e-05	0.000284	CcSEcCtD
Dabrafenib—Vomiting—Etoposide—lung cancer	2.93e-05	0.000282	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—lung cancer	2.93e-05	0.000282	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—lung cancer	2.93e-05	0.000282	CcSEcCtD
Dabrafenib—Rash—Etoposide—lung cancer	2.91e-05	0.00028	CcSEcCtD
Dabrafenib—Dermatitis—Etoposide—lung cancer	2.91e-05	0.00028	CcSEcCtD
Dabrafenib—Headache—Etoposide—lung cancer	2.89e-05	0.000278	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—lung cancer	2.88e-05	0.000278	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—lung cancer	2.88e-05	0.000278	CcSEcCtD
Dabrafenib—Vomiting—Paclitaxel—lung cancer	2.88e-05	0.000277	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	2.86e-05	0.000276	CcSEcCtD
Dabrafenib—Rash—Paclitaxel—lung cancer	2.85e-05	0.000275	CcSEcCtD
Dabrafenib—Dermatitis—Paclitaxel—lung cancer	2.85e-05	0.000274	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—lung cancer	2.84e-05	0.000273	CcSEcCtD
Dabrafenib—Headache—Paclitaxel—lung cancer	2.84e-05	0.000273	CcSEcCtD
Dabrafenib—Hypersensitivity—Docetaxel—lung cancer	2.83e-05	0.000272	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—lung cancer	2.82e-05	0.000271	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—lung cancer	2.76e-05	0.000266	CcSEcCtD
Dabrafenib—Asthenia—Docetaxel—lung cancer	2.75e-05	0.000265	CcSEcCtD
Dabrafenib—Infection—Methotrexate—lung cancer	2.75e-05	0.000264	CcSEcCtD
Dabrafenib—Nausea—Etoposide—lung cancer	2.74e-05	0.000264	CcSEcCtD
Dabrafenib—Pruritus—Docetaxel—lung cancer	2.71e-05	0.000261	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—lung cancer	2.71e-05	0.000261	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—lung cancer	2.71e-05	0.000261	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—lung cancer	2.71e-05	0.000261	CcSEcCtD
Dabrafenib—Nausea—Paclitaxel—lung cancer	2.69e-05	0.000259	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—lung cancer	2.69e-05	0.000258	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—lung cancer	2.67e-05	0.000257	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—lung cancer	2.63e-05	0.000253	CcSEcCtD
Dabrafenib—Diarrhoea—Docetaxel—lung cancer	2.62e-05	0.000253	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—lung cancer	2.58e-05	0.000249	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—lung cancer	2.56e-05	0.000246	CcSEcCtD
Dabrafenib—Dizziness—Docetaxel—lung cancer	2.54e-05	0.000244	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—lung cancer	2.53e-05	0.000244	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—lung cancer	2.52e-05	0.000242	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—lung cancer	2.5e-05	0.000241	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—lung cancer	2.5e-05	0.00024	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—lung cancer	2.5e-05	0.00024	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.48e-05	0.000239	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—lung cancer	2.44e-05	0.000235	CcSEcCtD
Dabrafenib—Vomiting—Docetaxel—lung cancer	2.44e-05	0.000235	CcSEcCtD
Dabrafenib—Rash—Docetaxel—lung cancer	2.42e-05	0.000233	CcSEcCtD
Dabrafenib—Dermatitis—Docetaxel—lung cancer	2.42e-05	0.000233	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—lung cancer	2.4e-05	0.000231	CcSEcCtD
Dabrafenib—Headache—Docetaxel—lung cancer	2.4e-05	0.000231	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—lung cancer	2.39e-05	0.00023	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—lung cancer	2.39e-05	0.00023	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—lung cancer	2.38e-05	0.000229	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—lung cancer	2.38e-05	0.000229	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—lung cancer	2.35e-05	0.000226	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—lung cancer	2.34e-05	0.000226	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—lung cancer	2.33e-05	0.000224	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—lung cancer	2.31e-05	0.000223	CcSEcCtD
Dabrafenib—Nausea—Docetaxel—lung cancer	2.28e-05	0.000219	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—lung cancer	2.26e-05	0.000218	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—lung cancer	2.24e-05	0.000215	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—lung cancer	2.19e-05	0.00021	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—lung cancer	2.19e-05	0.00021	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—lung cancer	2.18e-05	0.00021	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—lung cancer	2.17e-05	0.000208	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—lung cancer	2.08e-05	0.0002	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—lung cancer	2.07e-05	0.000199	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—lung cancer	2.06e-05	0.000199	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—lung cancer	2.05e-05	0.000197	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—lung cancer	2.04e-05	0.000196	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—lung cancer	1.98e-05	0.000191	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—lung cancer	1.96e-05	0.000188	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—lung cancer	1.96e-05	0.000188	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—lung cancer	1.89e-05	0.000182	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—lung cancer	1.89e-05	0.000182	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—lung cancer	1.89e-05	0.000182	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—lung cancer	1.83e-05	0.000176	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—lung cancer	1.76e-05	0.00017	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—lung cancer	1.76e-05	0.000169	CcSEcCtD
Dabrafenib—Rash—Methotrexate—lung cancer	1.74e-05	0.000168	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—lung cancer	1.74e-05	0.000168	CcSEcCtD
Dabrafenib—Headache—Methotrexate—lung cancer	1.73e-05	0.000167	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—lung cancer	1.72e-05	0.000165	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—lung cancer	1.69e-05	0.000163	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—lung cancer	1.64e-05	0.000158	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—lung cancer	1.64e-05	0.000158	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—lung cancer	1.58e-05	0.000152	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—lung cancer	1.52e-05	0.000147	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—lung cancer	1.51e-05	0.000145	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—lung cancer	1.51e-05	0.000145	CcSEcCtD
Dabrafenib—Headache—Doxorubicin—lung cancer	1.5e-05	0.000144	CcSEcCtD
Dabrafenib—Nausea—Doxorubicin—lung cancer	1.42e-05	0.000137	CcSEcCtD
Dabrafenib—ABCB1—Metabolism—GCLC—lung cancer	2.36e-06	2.63e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2A6—lung cancer	2.36e-06	2.63e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MAPK3—lung cancer	2.34e-06	2.6e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	2.32e-06	2.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FGFR1—lung cancer	2.31e-06	2.57e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP2E1—lung cancer	2.31e-06	2.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—lung cancer	2.3e-06	2.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—lung cancer	2.3e-06	2.56e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—APOA1—lung cancer	2.29e-06	2.55e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MDM2—lung cancer	2.28e-06	2.54e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NQO1—lung cancer	2.28e-06	2.54e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—lung cancer	2.28e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HIF1A—lung cancer	2.28e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RAF1—lung cancer	2.27e-06	2.53e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CG—lung cancer	2.26e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—lung cancer	2.26e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MDM2—lung cancer	2.25e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ERBB2—lung cancer	2.25e-06	2.5e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ENO1—lung cancer	2.24e-06	2.49e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	2.24e-06	2.49e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—RRM1—lung cancer	2.23e-06	2.49e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA3—lung cancer	2.23e-06	2.49e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	2.23e-06	2.48e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—lung cancer	2.23e-06	2.48e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTEN—lung cancer	2.23e-06	2.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERBB2—lung cancer	2.22e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MTOR—lung cancer	2.22e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CB—lung cancer	2.22e-06	2.47e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	2.21e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—lung cancer	2.21e-06	2.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—lung cancer	2.2e-06	2.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APOA1—lung cancer	2.2e-06	2.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTOR—lung cancer	2.19e-06	2.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CB—lung cancer	2.19e-06	2.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—lung cancer	2.19e-06	2.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—lung cancer	2.18e-06	2.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KDR—lung cancer	2.18e-06	2.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—lung cancer	2.17e-06	2.42e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—POMC—lung cancer	2.15e-06	2.39e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—lung cancer	2.13e-06	2.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—JUN—lung cancer	2.12e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—EP300—lung cancer	2.12e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—KRAS—lung cancer	2.1e-06	2.34e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—B4GALT5—lung cancer	2.1e-06	2.34e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	2.09e-06	2.33e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CREBBP—lung cancer	2.09e-06	2.33e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CG—lung cancer	2.09e-06	2.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CDKN1A—lung cancer	2.06e-06	2.29e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—STK11—lung cancer	2.06e-06	2.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTEN—lung cancer	2.05e-06	2.28e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA4—lung cancer	2.04e-06	2.27e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—lung cancer	2.04e-06	2.27e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—lung cancer	2.04e-06	2.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—lung cancer	2.03e-06	2.26e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2E1—lung cancer	2.01e-06	2.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KIT—lung cancer	2e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APC—lung cancer	2e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CG—lung cancer	2e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NRAS—lung cancer	2e-06	2.23e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA2—lung cancer	1.99e-06	2.22e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—POMC—lung cancer	1.99e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—lung cancer	1.99e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NQO1—lung cancer	1.99e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CD—lung cancer	1.99e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—JUN—lung cancer	1.98e-06	2.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGF—lung cancer	1.98e-06	2.2e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—lung cancer	1.96e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EP300—lung cancer	1.96e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—lung cancer	1.95e-06	2.17e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CREBBP—lung cancer	1.94e-06	2.16e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PIK3CA—lung cancer	1.93e-06	2.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—lung cancer	1.93e-06	2.15e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.93e-06	2.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CDKN1A—lung cancer	1.92e-06	2.14e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTA1—lung cancer	1.92e-06	2.14e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—MAPK3—lung cancer	1.92e-06	2.14e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTEN—lung cancer	1.92e-06	2.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—POMC—lung cancer	1.91e-06	2.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SRC—lung cancer	1.9e-06	2.12e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTP1—lung cancer	1.9e-06	2.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CDKN1A—lung cancer	1.9e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCC3—lung cancer	1.9e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTEN—lung cancer	1.9e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	1.89e-06	2.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BRAF—lung cancer	1.88e-06	2.1e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6R—lung cancer	1.86e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CREBBP—lung cancer	1.86e-06	2.07e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAT—lung cancer	1.85e-06	2.06e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.84e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKR1C1—lung cancer	1.84e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CD—lung cancer	1.84e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—lung cancer	1.84e-06	2.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NRAS—lung cancer	1.83e-06	2.04e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EP300—lung cancer	1.83e-06	2.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—lung cancer	1.83e-06	2.03e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—lung cancer	1.81e-06	2.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EP300—lung cancer	1.81e-06	2.01e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCB1—lung cancer	1.8e-06	2e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—STK11—lung cancer	1.79e-06	1.99e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—lung cancer	1.79e-06	1.99e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—UGT1A1—lung cancer	1.79e-06	1.99e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SRC—lung cancer	1.78e-06	1.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAP2K1—lung cancer	1.77e-06	1.97e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TYMS—lung cancer	1.77e-06	1.97e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CD—lung cancer	1.76e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SRC—lung cancer	1.76e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK3—lung cancer	1.75e-06	1.95e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GSTM1—lung cancer	1.75e-06	1.94e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—lung cancer	1.73e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CB—lung cancer	1.73e-06	1.93e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KRAS—lung cancer	1.73e-06	1.92e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GNG11—lung cancer	1.72e-06	1.92e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—lung cancer	1.72e-06	1.91e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—lung cancer	1.71e-06	1.91e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NRAS—lung cancer	1.71e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—lung cancer	1.71e-06	1.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—lung cancer	1.7e-06	1.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NRAS—lung cancer	1.69e-06	1.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—lung cancer	1.67e-06	1.86e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTP1—lung cancer	1.66e-06	1.84e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP1A1—lung cancer	1.66e-06	1.84e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ERCC2—lung cancer	1.64e-06	1.83e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALDOA—lung cancer	1.64e-06	1.82e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK3—lung cancer	1.64e-06	1.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MAPK3—lung cancer	1.62e-06	1.8e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAT—lung cancer	1.61e-06	1.79e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CB—lung cancer	1.6e-06	1.78e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—lung cancer	1.59e-06	1.77e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NCOA3—lung cancer	1.59e-06	1.77e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—lung cancer	1.59e-06	1.77e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CA—lung cancer	1.58e-06	1.76e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—lung cancer	1.58e-06	1.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MDM2—lung cancer	1.58e-06	1.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—KRAS—lung cancer	1.58e-06	1.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—lung cancer	1.58e-06	1.75e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CA—lung cancer	1.57e-06	1.75e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—lung cancer	1.56e-06	1.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB2—lung cancer	1.56e-06	1.73e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ADCY1—lung cancer	1.55e-06	1.72e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCG2—lung cancer	1.55e-06	1.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—lung cancer	1.54e-06	1.71e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TYMS—lung cancer	1.54e-06	1.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CB—lung cancer	1.54e-06	1.71e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MTOR—lung cancer	1.54e-06	1.71e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GSTM1—lung cancer	1.52e-06	1.69e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO2—lung cancer	1.52e-06	1.69e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HPGDS—lung cancer	1.52e-06	1.69e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.51e-06	1.68e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTEN—lung cancer	1.5e-06	1.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—lung cancer	1.48e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KRAS—lung cancer	1.47e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTT1—lung cancer	1.47e-06	1.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—lung cancer	1.47e-06	1.63e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GCLC—lung cancer	1.46e-06	1.62e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2A6—lung cancer	1.46e-06	1.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—KRAS—lung cancer	1.46e-06	1.62e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PIK3CA—lung cancer	1.45e-06	1.61e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP1A1—lung cancer	1.44e-06	1.61e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ERCC2—lung cancer	1.43e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—EP300—lung cancer	1.43e-06	1.59e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—APOA1—lung cancer	1.42e-06	1.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—lung cancer	1.41e-06	1.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—lung cancer	1.41e-06	1.57e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—lung cancer	1.4e-06	1.56e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTEN—lung cancer	1.38e-06	1.54e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO1—lung cancer	1.38e-06	1.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—lung cancer	1.38e-06	1.53e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—JUN—lung cancer	1.37e-06	1.53e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.36e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CA—lung cancer	1.35e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—lung cancer	1.34e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PIK3CA—lung cancer	1.34e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—lung cancer	1.33e-06	1.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CDKN1A—lung cancer	1.33e-06	1.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTEN—lung cancer	1.33e-06	1.48e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—EP300—lung cancer	1.32e-06	1.47e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—lung cancer	1.31e-06	1.46e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CG—lung cancer	1.3e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—lung cancer	1.29e-06	1.44e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—lung cancer	1.28e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—lung cancer	1.28e-06	1.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EP300—lung cancer	1.27e-06	1.41e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—lung cancer	1.25e-06	1.39e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—APOA1—lung cancer	1.24e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2E1—lung cancer	1.24e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—lung cancer	1.24e-06	1.38e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—POMC—lung cancer	1.24e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SRC—lung cancer	1.23e-06	1.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NQO1—lung cancer	1.22e-06	1.36e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CREBBP—lung cancer	1.2e-06	1.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—lung cancer	1.2e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—lung cancer	1.2e-06	1.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—lung cancer	1.19e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NRAS—lung cancer	1.18e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—lung cancer	1.18e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—lung cancer	1.18e-06	1.32e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CD—lung cancer	1.14e-06	1.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK3—lung cancer	1.13e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CG—lung cancer	1.13e-06	1.26e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—lung cancer	1.13e-06	1.25e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—lung cancer	1.11e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—STK11—lung cancer	1.1e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—lung cancer	1.1e-06	1.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—lung cancer	1.09e-06	1.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—lung cancer	1.08e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—POMC—lung cancer	1.08e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CA—lung cancer	1.05e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CREBBP—lung cancer	1.05e-06	1.17e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTP1—lung cancer	1.02e-06	1.14e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KRAS—lung cancer	1.02e-06	1.13e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CB—lung cancer	9.94e-07	1.11e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CD—lung cancer	9.94e-07	1.11e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAT—lung cancer	9.93e-07	1.11e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—lung cancer	9.85e-07	1.1e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—lung cancer	9.81e-07	1.09e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CA—lung cancer	9.77e-07	1.09e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCB1—lung cancer	9.66e-07	1.08e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TYMS—lung cancer	9.49e-07	1.06e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GSTM1—lung cancer	9.38e-07	1.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CA—lung cancer	9.36e-07	1.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—lung cancer	9.06e-07	1.01e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP1A1—lung cancer	8.89e-07	9.89e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ERCC2—lung cancer	8.82e-07	9.81e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—lung cancer	8.66e-07	9.64e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CB—lung cancer	8.66e-07	9.64e-06	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—lung cancer	8.62e-07	9.59e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTEN—lung cancer	8.59e-07	9.56e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—lung cancer	8.58e-07	9.55e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—lung cancer	8.29e-07	9.23e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—EP300—lung cancer	8.19e-07	9.12e-06	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—lung cancer	7.98e-07	8.88e-06	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—lung cancer	7.65e-07	8.51e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—APOA1—lung cancer	7.63e-07	8.49e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTEN—lung cancer	7.49e-07	8.33e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—EP300—lung cancer	7.14e-07	7.94e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CG—lung cancer	6.96e-07	7.75e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—POMC—lung cancer	6.63e-07	7.38e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CREBBP—lung cancer	6.46e-07	7.19e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CD—lung cancer	6.12e-07	6.81e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CA—lung cancer	6.06e-07	6.74e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—lung cancer	6.04e-07	6.73e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CB—lung cancer	5.34e-07	5.94e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—lung cancer	5.29e-07	5.88e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CA—lung cancer	5.28e-07	5.88e-06	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—lung cancer	4.95e-07	5.51e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTEN—lung cancer	4.61e-07	5.13e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—EP300—lung cancer	4.4e-07	4.89e-06	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—lung cancer	4.31e-07	4.8e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CA—lung cancer	3.25e-07	3.62e-06	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—lung cancer	2.66e-07	2.96e-06	CbGpPWpGaD
